57 related articles for article (PubMed ID: 24752449)
1. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
Wakui H; Yamamoto N; Kitazono S; Mizugaki H; Nakamichi S; Fujiwara Y; Nokihara H; Yamada Y; Suzuki K; Kanda H; Akinaga S; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):15-23. PubMed ID: 24752449
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
Arkenau HT; Plummer R; Molife LR; Olmos D; Yap TA; Squires M; Lewis S; Lock V; Yule M; Lyons J; Calvert H; Judson I
Ann Oncol; 2012 May; 23(5):1307-1313. PubMed ID: 22015452
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Siu LL; Pili R; Duran I; Messersmith WA; Chen EX; Sullivan R; MacLean M; King S; Brown S; Reid GK; Li Z; Kalita AM; Laille EJ; Besterman JM; Martell RE; Carducci MA
J Clin Oncol; 2008 Apr; 26(12):1940-7. PubMed ID: 18421048
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.
Kondo S; Katsuya Y; Yonemori K; Komuro K; Sugeno M; Kawata T; Ghiorghiu D; Meulendijks D; Yamamoto N
Cancer Treat Res Commun; 2024; 39():100809. PubMed ID: 38593512
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors.
Esaki T; Seto T; Ariyama H; Arita S; Fujimoto C; Tsukasa K; Kometani T; Nosaki K; Hirai F; Yagawa K
Arch Drug Inf; 2011 Jun; 4(2):23-31. PubMed ID: 21765863
[TBL] [Abstract][Full Text] [Related]
6. A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group.
Sibille M; Patat A; Caplain H; Donazzolo Y
Br J Clin Pharmacol; 2010 Nov; 70(5):736-48. PubMed ID: 21039768
[TBL] [Abstract][Full Text] [Related]
7. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
Infante JR; Patnaik A; Verschraegen CF; Olszanski AJ; Shaheen M; Burris HA; Tolcher AW; Papadopoulos KP; Beeram M; Hynes SM; Leohr J; Lin AB; Li LQ; McGlothlin A; Farrington DL; Westin EH; Cohen RB
Cancer Chemother Pharmacol; 2017 Feb; 79(2):315-326. PubMed ID: 28097385
[TBL] [Abstract][Full Text] [Related]
8. The cytoplasmic tail of rhodopsin triggers rapid rod degeneration in kinesin-2 mutants.
Feng D; Chen Z; Yang K; Miao S; Xu B; Kang Y; Xie H; Zhao C
J Biol Chem; 2017 Oct; 292(42):17375-17386. PubMed ID: 28855254
[TBL] [Abstract][Full Text] [Related]
9. The armadillo protein p0071 controls KIF3 motor transport.
Becher A; Eiseler T; Porzner M; Walther P; Keil R; Bobrovich S; Hatzfeld M; Seufferlein T
J Cell Sci; 2017 Oct; 130(19):3374-3387. PubMed ID: 28808088
[TBL] [Abstract][Full Text] [Related]
10. The Pyruvate Dehydrogenase Complex and Related Assemblies in Health and Disease.
Byron O; Lindsay JG
Subcell Biochem; 2017; 83():523-550. PubMed ID: 28271489
[TBL] [Abstract][Full Text] [Related]
11. Pyruvate dehydrogenase-E1α deficiency presenting as recurrent acute proximal muscle weakness of upper and lower extremities in an 8-year-old boy.
Kara B; Genç HM; Uyur-Yalçın E; Sakarya-Güneş A; Topçu U; Mülayim S; Ceylaner S
Neuromuscul Disord; 2017 Jan; 27(1):94-97. PubMed ID: 27894792
[TBL] [Abstract][Full Text] [Related]
12. Structural alterations induced by ten disease-causing mutations of human dihydrolipoamide dehydrogenase analyzed by hydrogen/deuterium-exchange mass spectrometry: Implications for the structural basis of E3 deficiency.
Ambrus A; Wang J; Mizsei R; Zambo Z; Torocsik B; Jordan F; Adam-Vizi V
Biochim Biophys Acta; 2016 Nov; 1862(11):2098-2109. PubMed ID: 27544700
[TBL] [Abstract][Full Text] [Related]
13. Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene.
Bayrakli F; Poyrazoglu HG; Yuksel S; Yakicier C; Erguner B; Sagiroglu MS; Yuceturk B; Ozer B; Doganay S; Tanrikulu B; Seker A; Akbulut F; Ozen A; Per H; Kumandas S; Altuner Torun Y; Bayri Y; Sakar M; Dagcinar A; Ziyal I
J Hum Genet; 2015 Dec; 60(12):763-8. PubMed ID: 26423925
[TBL] [Abstract][Full Text] [Related]
14. Discontinued in 2013: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2015 Jan; 24(1):95-110. PubMed ID: 25315907
[TBL] [Abstract][Full Text] [Related]
15. Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.
Ding S; Zhao Z; Sun D; Wu F; Bi D; Lu J; Xing N; Sun L; Wu H; Ding K
Tumour Biol; 2014 Aug; 35(8):7659-68. PubMed ID: 24801905
[TBL] [Abstract][Full Text] [Related]
16. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
[TBL] [Abstract][Full Text] [Related]
17. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Ocio EM; Motlló C; Rodríguez-Otero P; Martínez-López J; Cejalvo MJ; Martín-Sánchez J; Bladé J; García-Malo MD; Dourdil MV; García-Mateo A; de Arriba F; García-Sanz R; de la Rubia J; Oriol A; Lahuerta JJ; San-Miguel JF; Mateos MV
Br J Haematol; 2021 Feb; 192(3):522-530. PubMed ID: 32501528
[TBL] [Abstract][Full Text] [Related]
18. Mitotic Functions and Characters of KIF11 in Cancers.
Gao W; Lu J; Yang Z; Li E; Cao Y; Xie L
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672404
[TBL] [Abstract][Full Text] [Related]
19. The two sides of chromosomal instability: drivers and brakes in cancer.
Hosea R; Hillary S; Naqvi S; Wu S; Kasim V
Signal Transduct Target Ther; 2024 Mar; 9(1):75. PubMed ID: 38553459
[TBL] [Abstract][Full Text] [Related]
20. Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies.
Shahin R; Aljamal S
Future Sci OA; 2022 Mar; 8(3):FSO778. PubMed ID: 35251692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
